Zyus Life Sciences Corporation (TSE:ZYUS) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ZYUS Life Sciences Corporation, a Canadian life sciences firm, has been granted a U.S. patent for its novel cannabinoid-based pain management drug, Trichomylin® softgel capsules. This addition to ZYUS’ growing intellectual property portfolio marks a significant milestone in the company’s pursuit of non-opioid pain treatments. The patent represents the company’s commitment to innovation and the development of alternative therapies for pain management.
For further insights into TSE:ZYUS stock, check out TipRanks’ Stock Analysis page.
